Joe Grogan is a healthcare expert with a unique blend of private sector and government experience spanning over two decades in the Washington, D.C. healthcare arena. He has played a major role in some of the most significant healthcare policy fights and dramas that America has faced in recent memory. From running the Washington D.C. office of Gilead Sciences, Inc. during the launch of Sovaldi for Hepatitis C–the most lucrative and controversial drug launch in history–to serving on the White House Covid-19 task force during the first critical months of the pandemic, Joe brings a unique perspective as someone who has seen healthcare policy from both within corporations and as a policy maker.
In the George W. Bush Administration, he started his healthcare career at the Department of Health and Human services working on issues affecting the social determinants of health and economic empowerment. He went on to serve as Executive Director of the President's Advisory Council on HIV and AIDS, where he first collaborated with many of the same scientists and companies who would play a such a pivotal role in the Covid-19 pandemic years later. Finally, he served at the Food and Drug Administration as a Senior Policy Advisor where he confronted major public health scares stemming from tainted medical products originating in China, as well as critical policy issues such as the reauthorization of the Prescription Drug User Fee Act.
After leaving the Bush Administration, he served as a consultant to Wall Street investors before joining Amgen and ultimately Gilead Sciences. In the Trump Administration, Grogan took a major role in shaping healthcare policy as Associate Director for Health Programs managing a budget of over 1.3 trillion domestic health spending. In his two years in this role, Grogan shaped every major regulation issued by the Department of Health and Human Services. Ultimately, he assumed the role of Assistant to President Trump and Director of the Domestic Policy Council where he is widely credited with reinvigorating the office and turning around an office that was in disarray. Upon leaving the White House in May, he has consulted for some of America's most important health care companies. He is frequently called upon by corporate management as well as leaders on Capitol Hill. Joseph has been published in the WSJ, Newsweek, and many other widely read publications.